Editorial on immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

Immunotherapy. 2023 Nov;15(16):1323-1326. doi: 10.2217/imt-2023-0161. Epub 2023 Sep 11.

Authors

Samantha M Ruff¹, Timothy M Pawlik¹

Affiliation

¹ Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center & James Comprehensive Cancer Center, Columbus, OH 43210, USA.

PMID: 37694380
DOI: 10.2217/imt-2023-0161

No abstract available

Keywords: atezolizumab; bevacizumab; hepatocellular carcinoma; immune checkpoint inhibitor; immunotherapy; liver cancer.

Publication types

Editorial

MeSH terms

Bevacizumab
Carcinoma, Hepatocellular* / drug therapy
Humans
Immune Checkpoint Inhibitors / therapeutic use
Liver Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Bevacizumab